Inhaled diazeniumdiolates (NONOates) as selective pulmonary vasodilators

Expert Opinion on Investigational Drugs

Volumn 11, Issue 7, 2002, Pages 897-909

  Lam, Chen Fuh ^a   Sviri, Sigal ^a   Ilett, Kenneth F ^a   van Heerden, Peter V ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Asthma; Nitric oxide; NONOates; Pulmonary hypertension; Selective pulmonary vasodilators

Indexed keywords

ARGININE; DIAZENIUMDIOLATE DERIVATIVE; GUANOSINE PHOSPHATE; GUANYLATE CYCLASE; NITRIC OXIDE; PHOSPHODIESTERASE; PROSTACYCLIN; UNCLASSIFIED DRUG; VASODILATOR AGENT; AZO COMPOUND; DIAZENIUMDIOLATE; NITRIC OXIDE DONOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ASTHMA; CIRCULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SELECTIVITY; DRUG STRUCTURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG BLOOD VESSEL; LUNG EDEMA; LUNG HEMORRHAGE; LUNG TOXICITY; LUNG VENTILATION; LUNG VENTILATION PERFUSION RATIO; METHEMOGLOBINEMIA; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; VASODILATATION; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; INHALATIONAL DRUG ADMINISTRATION; LUNG CIRCULATION; PHYSIOLOGY;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ANIMAL; ASTHMA; AZO COMPOUNDS; CHRONIC DISEASE; HUMAN; HYPERTENSION, PULMONARY; NITRIC OXIDE; NITRIC OXIDE DONORS; PULMONARY CIRCULATION; RESPIRATORY DISTRESS SYNDROME, ADULT; VASODILATOR AGENTS; ANIMALS; HUMANS;

EID: 0035986892     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.7.897     Document Type: Review

References (92)

1. Pulmonary circulation and lung fluid and solute exchange
2. Anatomy
3. Regulation of vascular tone
4. Diagnosis and treatment of pulmonary hypertension
5. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: Incidence, clinical implications, and prognosis
6. Chronic cor pulmonale. Etiology and management
7. Contrasting acute effects of vasodilators (nitroglycerin, nitroprusside, and hydralazine) on right ventricular performance in patients with chronic obstructive pulmonary disease and pulmonary hypertension: A radionuclide-hemodynamic study
8. Inhaled and exhaled nitric oxide
9. Inhaled nitric oxide
10. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS
11. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
12. Adenosine is a selective pulmonary vasodilator in cardiac surgical patients
13. Inhalation of nebulized nitroglycerin in dogs with experimental pulmonary hypertension induced by U46619
14. Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets
15. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension
16. Chemistry of nitric oxide: Biologically relevant aspects
17. Inhaled nitric oxide: Basic biology and clinical applications
18. Nitric oxide in the lung: Therapeutic and cellular mechanisms of action
19. Inhaled 'endothelium derived-relaxing factor' (EDRF) in primary hypertension
20. Inhaled nitric oxide for the adult respiratory distress syndrome
21. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure
22. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide
23. UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs
24. NONOates (1-substituted Diazen-1-ium-1,2-diolates) as nitric oxide donors; convenient nitric oxide dosage forms
25. Diazeniumdiolates: Pro- and antioxidant applications of the 'NONOates'
26. Intratracheal instillation of a novel NO/nucleophile adduct selectively reduces pulmonary hypertension
27. Pulmonary vasodilation by nitric oxide gas and prodrug aerosols in acute pulmonary hypertension
28. The acute respiratory distress syndrome
29. Pathogenesis and treatment of the adult respiratory distress syndrome
30. Surfactant abnormalities in patients with respiratory failure after multiple trauma
31. Hypoxic pulmonary vasoconstriction in the adult respiratory distress syndrome
32. Response to inhaled nitric oxide in patients with acute right heart syndrome
33. Acute respiratory distress syndrome
34. The acute respiratory distress syndrome
35. Nitric oxide in adult lung disease
36. Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension
37. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury
38. Aerosolization of novel nitric oxide donors selectively reduce pulmonary hypertension
39. Soluble nitric oxide donor and surfactant improve oxygenation and pulmonary hypertension in porcine lung injury
40. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome
41. The effects of inhalation of a novel nitric oxide donor, DETA/NO in a patient with severe hypoxaemia due to the acute respiratory distress syndrome
42. Primary pulmonary hypertension
43. Pulmonary hypertension: Its assessment and treatment
44. Nitric oxide (NO) donor molecules: Effect of NO release rate on vascular smooth muscle cell proliferation in vitro
45. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat
46. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats
47. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups
48. Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension
49. Primary pulmonary hypertension
50. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
51. Alpha1-adrenergic hypothesis for pulmonary hypertension
52. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
53. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension
54. One-year continuous inhaled nitric oxide for primary pulmonary hypertension
55. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension. An ambulatory delivery system and initial clinical tests
56. How to manage secondary pulmonary hypertension. Recognizing and treating cor pulmonale and chronic thromboembolism
57. Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management
58. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two
59. Addition of nitric oxide to oxygen improves cardiopulmonary function in patients with severe COPD
60. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension
61. Inhaled nitric oxide does not improve cardiac or pulmonary function in patients with an exacerbation of chronic obstructive pulmonary disease
62. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease
63. Inhaled nitric oxide for right ventricular dysfunction in chronic obstructive pulmonary disease patients: Fall or rise of an idea?
64. Bronchodilator action of inhaled nitric oxide in guinea pigs
65. Nitric oxide and airway disease
66. Nitric oxide and bronchial reactivity
67. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans
68. Inhibition by L-NG-nitro-L-arginine of nonadrenergic-noncholinergic-mediated relaxations of human isolated central and peripheral airway
69. Effects of inhaled nitric oxide on methacholine-induced bronchoconstriction: A concentration response study in rabbits
70. Reversal of bronchoconstriction by inhaled nitric oxide. Histamine versus methacholine
71. Inhaled nitric oxide attenuates bronchoconstriction in canine peripheral airways
72. Inhaled nitric oxide. A bronchodilator in mild asthmatics with methacholine-induced bronchospasm
73. Bronchodilator effect of inhaled nitric oxide in healthy men
74. The effect of inhaled nitric oxide in pediatric asthma
75. NO or no NO in asthma?
76. Modulation of cholinergic neural bronchoconstriction by endogenous nitric oxide and vasoactive intestinal peptide in human airways in vitro
77. The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea-pig airways
78. Nitric oxide in asthma. Pathogenic, therapeutic, or diagnostic?
79. Exhaled nitric oxide production by nitric oxide synthase-deficient mice
80. Inhibition of allergic airway inflammation in mice lacking nitric oxide synthase 2
81. Use of nitric oxide-nucleophile adducts as biological sources of nitric oxide: Effects on airway smooth muscle
82. Polyamines and putreanine relax respiratory tract smooth muscle in the guinea-pig
83. Toxicity and complications of inhaled nitric oxide
84. Effects of higher oxides of nitrogen on the anaesthetized dog
85. 2-induced lung injury in rats
86. Effects of long-term nitrogen dioxide exposure on rat lung: Morphological observations
87. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide
88. Inhaled nitric oxide promes lung macrophages to produce reactive oxygen and nitrogen intermediates
89. Methemoglobinemia: Etiology, pharmacology, and clinical management
90. Polyamines in clinical and basic science: Introductory remarks
91. Target cell toxicity of inhaled spermidine in rat lungs
92. Effects of diethylenetriamine dihydrochloride following 13 weeks of dietary dosing in Fischer 344 rats